Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD. (2026). SKIN The Journal of Cutaneous Medicine, 10(2), s731. https://doi.org/10.25251/26swpe94